Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG’s NucleoCapture and HemoNucleoCapture Devices

February 21, 2024

https://www.prnewswire.com/news-releases/aethlon-medical-enters-into-materials-transfer-agreement-for-santersus-ags-nucleocapture-and-hemonucleocapture-devices-302067186.html

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System

SAN DIEGO, Feb. 21, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich–London based, privately held therapeutic medical device company, for Santersus’ NucleoCapture and HemoNucleoCapture devices.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.